Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients

Author:

Lehrer Eric J.1,Ahluwalia Manmeet S.2,Gurewitz Jason3,Bernstein Kenneth3,Kondziolka Douglas4,Niranjan Ajay5,Wei Zhishuo5,Lunsford L. Dade5,Fakhoury Kareem R.6,Rusthoven Chad G.6,Mathieu David7,Trudel Claire8,Malouff Timothy D.9,Ruiz-Garcia Henry9,Bonney Phillip7,Hwang Lindsay10,Yu Cheng7,Zada Gabriel7,Patel Samir11,Deibert Christopher P.12,Picozzi Piero13,Franzini Andrea13,Attuati Luca13,Prasad Rahul N.14,Raval Raju R.14,Palmer Joshua D.14,Lee Cheng-Chia15,Yang Huai-Che15,Jones Brianna M.1,Green Sheryl1,Sheehan Jason P.16,Trifiletti Daniel M.9

Affiliation:

1. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York;

2. Department of Medical Oncology, Miami Cancer Institute, Miami, Florida;

3. Departments of Radiation Oncology and

4. Neurosurgery, NYU Langone Medical Center, New York, New York;

5. Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;

6. Department of Radiation Oncology, University of Colorado, Aurora, Colorado;

7. Departments of Neurosurgery and

8. Medicine, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada;

9. Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida;

10. Radiation Oncology, University of Southern California, Los Angeles, California;

11. Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada;

12. Department of Neurological Surgery, Emory University, Atlanta, Georgia;

13. Department of Neurosurgery, IRCCS Humanitas Research Hospital, Rozzano, Italy;

14. Department of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, Ohio;

15. Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; and

16. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia

Abstract

OBJECTIVE Immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS) are commonly utilized in the management of brain metastases. Treatment-related imaging changes (TRICs) are a frequently observed clinical manifestation and are commonly classified as imaging-defined radiation necrosis. However, these findings are not well characterized and may predict a response to SRS and ICIs. The objective of this study was to investigate predictors of TRICs and their impact on patient survival. METHODS This retrospective multicenter cohort study was conducted through the International Radiosurgery Research Foundation. Member institutions submitted de-identified clinical and dosimetric data for patients with non–small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) brain metastases that had been treated with SRS and ICIs. Data were collected from March 2020 to February 2021. Univariable and multivariable Cox and logistic regression analyses were performed. The Kaplan-Meier method was used to evaluate overall survival (OS). The diagnosis-specific graded prognostic assessment was used to guide variable selection. TRICs were determined on the basis of MRI, PET/CT, or MR spectroscopy, and consensus by local clinical providers was required. RESULTS The analysis included 697 patients with 4536 brain metastases across 11 international institutions in 4 countries. The median follow-up after SRS was 13.6 months. The median age was 66 years (IQR 58–73 years), 54.1% of patients were male, and 57.3%, 36.3%, and 6.4% of tumors were NSCLC, melanoma, and RCC, respectively. All patients had undergone single-fraction radiosurgery to a median margin dose of 20 Gy (IQR 18–20 Gy). TRICs were observed in 9.8% of patients. The median OS for all patients was 24.5 months. On univariable analysis, Karnofsky Performance Status (KPS; HR 0.98, p < 0.001), TRICs (HR 0.67, p = 0.03), female sex (HR 0.67, p < 0.001), and prior resection (HR 0.60, p = 0.03) were associated with improved OS. On multivariable analysis, KPS (HR 0.98, p < 0.001) and TRICs (HR 0.66, p = 0.03) were associated with improved OS. A brain volume receiving ≥ 12 Gy of radiation (V12Gy) ≥ 10 cm3 (OR 2.78, p < 0.001), prior whole-brain radiation therapy (OR 3.46, p = 0.006), and RCC histology (OR 3.10, p = 0.01) were associated with an increased probability of developing TRICs. The median OS rates in patients with and without TRICs were 29.0 and 23.1 months, respectively (p = 0.03, log-rank test). CONCLUSIONS TRICs following ICI and SRS were associated with a median OS benefit of approximately 6 months in this retrospective multicenter study. Further prospective study and additional stratification are needed to validate these findings and further elucidate the role and etiology of this common clinical scenario.

Publisher

Journal of Neurosurgery Publishing Group (JNSPG)

Subject

Genetics,Animal Science and Zoology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3